

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*  
**022410Orig1s000**

**REMS**

**NDA 22-410**  
**SUBOXONE® (buprenorphine and naloxone) sublingual film CIII**  
**Buprenorphine (opioid partial agonist-antagonist)**

**Naloxone (opioid antagonist)**

Reckitt Benckiser Pharmaceuticals Inc.

10710 Midlothian Turnpike, Suite 430

Richmond, VA 23235

Telephone: 804-379-1090

**RISK EVALUATION AND MITIGATION STRATEGY (REMS)**

*This REMS does not apply to SUBOXONE film dispensed to patients admitted to an Opioid Treatment Program under 42 CFR Part 8.*

**I. GOAL(S):**

The goals of the SUBOXONE film risk evaluation and mitigation strategy are to:

- Mitigate the risks of accidental overdose, misuse and abuse
- Inform patients of the serious risks associated with SUBOXONE film

**II. REMS ELEMENTS:**

**A. Medication Guide**

A Medication Guide will be dispensed with each SUBOXONE film prescription in accordance with 21 CFR 208.24.

**B. Elements to Assure Safe Use**

**1. Safe use conditions**

- a. SUBOXONE film will only be dispensed by the prescriber or prescribed to patients with documentation of the following safe use conditions:
  - i. Verification that the patient meets the diagnostic criteria for opioid dependence.

- ii. Risks described in the professional labeling and the Medication Guide have been discussed with the patient.
  - iii. Safe storage of the medication has been explained and reviewed with the patient.
  - iv. After appropriate induction, the patient is prescribed a limited amount of medication at the first visit.
- b. Prescribers will document safe use conditions for each patient by using the '[Appropriate Use Checklist](#),' or by using another method (e.g. electronic health record) specific to the prescriber's office practice.
  - c. Reckitt Benckiser Pharmaceuticals Inc. will ensure that within 30 days of FDA approval of the SUBOXONE REMS, a [REMS Instruction Letter to Prescribers](#) will be mailed to all physicians certified to treat opioid dependence under the Drug Addiction Treatment Act of 2000 (DATA 2000). This letter is designed to convey and reinforce the risks of accidental overdose, misuse, and abuse of SUBOXONE, as well as the need to appropriately monitor patients and document safe use conditions.
  - d. Reckitt Benckiser Pharmaceuticals Inc. will, on a monthly basis, identify any newly DATA 2000-certified physicians and mail the applicable documents to them. The following materials will be appended to the [Prescriber Instruction Letter: Medication Guide, Full Prescribing Information, Physician Brochure](#), and the [Appropriate Use Checklist](#).
  - e. To further reinforce safe use conditions, Reckitt Benckiser Pharmaceuticals Inc. will ensure that within 30 days of FDA approval of the SUBOXONE REMS, a REMS Introductory Letter for Pharmacists will be mailed to all pharmacists on a national mailing list from the American Pharmacists Association. The following materials will be appended to the [Introductory Pharmacist Letter: Medication Guide, Full Prescribing Information and the Pharmacist Brochure](#).

- f. Reckitt Benckiser Pharmaceuticals Inc. will make the letters and all materials that are appended to the letters available through its toll-free information line, through its field personnel, and on the product website.

## 2. Monitoring

- a. Each patient using SUBOXONE film will be subject to the following monitoring:
  - i. Return visits are scheduled at intervals commensurate with patient stability. Weekly, or more frequent, visits are recommended for the first month.
  - ii. Assessment and reinforcement of patient's compliance with the prescribed medication.
  - iii. Assessment of appropriateness of dosage prescribed.
  - iv. Assessment of whether patient is receiving the necessary psychosocial support.
  - v. Assessment of whether patient is making adequate progress towards treatment goals.
- b. Prescribers will document that each patient has received the required clinical monitoring using the '[Appropriate Use Checklist](#),' or by using another method/system (e.g. electronic health record) specific to the prescriber's office practice.

The following materials are part of the [REMS](#) and are appended to the REMS document:

- [SUBOXONE film Medication Guide](#)
- [REMS Instruction Letter to Prescribers](#)
- [REMS Introductory Letter to Pharmacists](#)
- [Appropriate Use Checklist](#)
- [Physician Brochure](#), "*Important Information for Physicians-Frequently Asked Questions*"

- [Pharmacist Brochure](#), “*Important Information for Pharmacists-Frequently Asked Questions*”

**C. Implementation System**

The Implementation System includes the following:

1. Reckitt Benckiser Pharmaceuticals Inc. will ensure that all DATA 2000-certified physicians receive the Instruction Letter with the appended materials.
2. Reckitt Benckiser Pharmaceuticals Inc. will monitor compliance with the requirements to document prescribing and dispensing with documentation of safe use conditions through surveys of patients and prescribers, evaluations of health care utilization databases, and ongoing surveillance (sources including, but not limited to, internet, street ethnography, national databases, and surveys conducted at substance abuse treatment programs).
3. Reckitt Benckiser Pharmaceuticals Inc. will monitor and evaluate the implementation of the elements to assure safe use provided for under Sections [B1](#), above, and in the manner described in the REMS supporting document, and will take reasonable steps to improve implementation of these elements to meet the goals of the REMS.

**D. Timetable for Submission of Assessments**

Reckitt Benckiser Pharmaceuticals Inc. will submit REMS Assessments to FDA at 6 months and at 12 months for the first year from the date of approval of the REMS, then annually thereafter. To facilitate inclusion of as much information as possible, while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment will conclude no earlier than 60 days before the submission date for that assessment. Reckitt Benckiser Pharmaceuticals Inc. will submit each assessment so it will be received by the FDA on or before the due date.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.